
CLGN Stock Forecast & Price Target
CLGN Analyst Ratings
Bulls say
CollPlant Biotechnologies is poised for growth due to strategic corporate initiatives aimed at enhancing its rhCollagen supply and accelerating North American operations through key appointments. The company's advancements in regenerative breast implants position it competitively for first-to-market opportunities within a lucrative addressable market, further solidifying its potential for revenue growth. Additionally, the new distribution agreement in Poland for the Vergenix STR product enhances its market presence across Europe, expanding its revenue-generating capabilities in multiple regions.
Bears say
CollPlant Biotechnologies Ltd shows concerning financial metrics, particularly in its revenue generation across its key markets, which include the United States, Canada, Europe, and Israel. The company's reliance on business collaborators and sales from a niche product line, such as its BioInk for 3D bioprinting, raises uncertainty regarding sustained revenue growth amidst a competitive landscape. Additionally, fluctuating demand in the medical aesthetics market and emerging challenges in product commercialization could hinder the company's ability to achieve consistent profitability.
This aggregate rating is based on analysts' research of CollPlant Biotechnologies Ltd - ADR and is not a guaranteed prediction by Public.com or investment advice.
CLGN Analyst Forecast & Price Prediction
Start investing in CLGN
Order type
Buy in
Order amount
Est. shares
0 shares